Clinical trials: Hyperlipoproteinemia (a)
Hypertension,, Hyperlipidemia
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and…
- Trial name
- NCT01918332
- Testing
- Valsartan 160mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 168 people
- Sponsor
- LG Life Sciences
Homozygous Familial Hypercholesterolemia (HoFH)
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients
Significant reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead to the reduction of risk of coronary heart disease and cardiovascular events associated with hypertriglyceridemia and LDL-C in…
- Trial name
- NCT06712771
- Testing
- VSA003
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Visirna Therapeutics HK Limited
Hyperlipidemia
Differential Effects of a Diet Supplementation With Plant Sterol Esters on Human Monocytes
The purpose of this study is to evaluate the effects of a diet supplementation with plant sterol esters on serum lipids, plant sterol concentrations and monocyte subpopulations.
- Trial name
- PSE-MO (NCT00928616)
- Testing
- margarine + plant sterol esters
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Saarland
Homozygous Familial Hypercholesterolemia
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR…
- Trial name
- NCT06125847
- Testing
- NGGT006
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Glycemia, Hypertension
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care…
- Conditions
- Glycemia, Hypertension, Hyperlipidemia
- Trial name
- PATROL (NCT00891124)
- Where
- 7 sites in South Korea
- Volunteers
- 4,045 people
- Sponsor
- AstraZeneca
Hyperlipidemia
Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002
This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002 and the routes and rates of excretion of [14C]-ETC-1002
- Trial name
- NCT02044627
- Testing
- [14C-ETC-1002]
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Esperion Therapeutics, Inc.
Hyperlipoproteinemia(a), Progressive Cardiovascular Disease
Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a)
Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. Non-medical treatment measures (e.g. dietary therapy or weight loss) can hardly influence Lp(a) plasma concentrations.
- Trial name
- ELAILa (NCT01064934)
- Testing
- Lipid apheresis, Standard care
- Where
- Germany
- Sponsor
- Charite University, Berlin, Germany
Familial Chylomicronemia
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS).
- Trial name
- PALISADE (NCT05089084)
- Testing
- Plozasiran
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 75 people
- Sponsor
- Arrowhead Pharmaceuticals
Hyperlipidemia
Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine
The goal of this clinical trial is to learn if berberine works to affect lipids and lipoproteins in Chinese females aged 20 to 65 years with hyperlipidaemia.
- Trial name
- NCT06782646
- Testing
- Berberine
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
Diabetes, Hyperlipidemia
Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers
A randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteers.
- Trial name
- NCT02449187
- Testing
- JLP-1310, Fasted followed by fed, JLP-1310, Fed followed by fasted
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
- Trial name
- SPIRE-LDL (NCT01968967)
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 249 sites in United States, Canada and 10 more
- Volunteers
- 2,139 people
- Sponsor
- Pfizer
Healthy Participants, Hyperlipidemia
A Phase 1 Study of VELA-101 in Adult Participants
This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses…
- Trial name
- NCT07864311
- Testing
- VELA-101
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ursa Medicines
Hyperlipidemia
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen).
- Trial name
- SPIRE-AI (NCT02458287)
- Testing
- Bococizumab 150mg, Bococizumab 75mg
- Where
- 30 sites in United States
- Volunteers
- 299 people
- Sponsor
- Pfizer
Type 2 Diabetes, Hypertension
Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative
The goal of this study is to evaluate the effectiveness of a multi-level health-related social needs (HRSN) initiative among adult patients diagnosed with type 2 diabetes, plus hypertension or hyperlipidemia.
- Conditions
- Type 2 Diabetes, Hypertension, Hyperlipidemia, Health-related Social Problems
- Trial name
- NCT06831162
- Testing
- Multi-level HRSN initiative
- Where
- United States
- Volunteers
- 6,928 people
- Sponsor
- Vanderbilt University Medical Center
Preventative Medicine
Using a Telehealth and Shared Decision-Making Model to Address Preventative Medicine Strategies Among Communities in Louisiana
This study is a 12-18 month behavioral intervention study to assess the impact of enrolling individuals a clinical pharmacist run Telehealth education focused on wellness and preventive health strategies.
- Trial name
- NCT05676970
- Testing
- Telehealth: Personalized Preventative Medicine Strategies, TeleHealth: Preventative Medicine Education
- Where
- United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Xavier University of Louisiana.
Hyperlipidemia
Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Evaluation of the efficacy and safety of multiple subcutaneous injections of SHR-1918 in patients with hyperlipidemia in poor control: a multicenter, randomized, double-blind, placebo-controlled phase II clinical trials
- Trial name
- NCT06471218
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipoproteinemia
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia
The purpose of this study is to evaluate the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A （CoA） capsule in Chinese patients with moderate dyslipidemia.
- Trial name
- NCT01645046
- Testing
- Coenzyme A
- Volunteers
- 294 people
- Sponsor
- Zhejiang University
Familial Hypercholesterolemia, Cardiac Event
Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry
Familial hypercholesterolaemia (FH) is an autosomal dominant somatic mutation commonly located on the LDL-receptor, APOB, and PCKS9 gene.
- Conditions
- Familial Hypercholesterolemia, Cardiac Event, Percutaneous Coronary Intervention
- Trial name
- NCT02778646
- Volunteers
- 1,622,948 people
- Sponsor
- University College, London
Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Recessive
Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis
This pilot study investigates integrating whole genome sequencing and digital twin technology for managing hypercholesterolemia in Abu Dhabi clinics.
- Conditions
- Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Recessive, Familial Combined Hypercholesterolemia
- Trial name
- NCT06535542
- Testing
- Whole Genome Sequencing
- Where
- United Arab Emirates
- Volunteers
- 40 people
- Sponsor
- Abu Dhabi Health Services Company
Hypercholesterolemia
Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
- Trial name
- NCT02585895
- Testing
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 39 people
- Sponsor
- Amgen